Viatris Free cash flow decreased by 43.7% to $348.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 29.3%, from $492.90M to $348.40M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -6.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $470.10M | $964.60M | $325.70M | $1.07B | $718.60M | $765.10M | $35.30M | $923.40M | $457.30M | $739.30M | $403.00M | $564.80M | $320.30M | $749.50M | $342.30M | $492.90M | $166.80M | $658.10M | $619.30M | $348.40M |
| QoQ Change | — | +105.2% | -66.2% | +229.8% | -33.1% | +6.5% | -95.4% | >999% | -50.5% | +61.7% | -45.5% | +40.1% | -43.3% | +134.0% | -54.3% | +44.0% | -66.2% | +294.5% | -5.9% | -43.7% |
| YoY Change | — | — | — | — | +52.9% | -20.7% | -89.2% | -14.0% | -36.4% | -3.4% | >999% | -38.8% | -30.0% | +1.4% | -15.1% | -12.7% | -47.9% | -12.2% | +80.9% | -29.3% |